Adverse reactions to the non-drug constituents of nebuliser solutions.
作者信息
Beasley R, Rafferty P, Holgate S T
机构信息
Immunopharmacology Group, Southampton General Hospital.
出版信息
Br J Clin Pharmacol. 1988 Mar;25(3):283-7. doi: 10.1111/j.1365-2125.1988.tb03305.x.
Abstract
摘要
相似文献
1
Adverse reactions to the non-drug constituents of nebuliser solutions.
Br J Clin Pharmacol. 1988 Mar;25(3):283-7. doi: 10.1111/j.1365-2125.1988.tb03305.x.
2
A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions.
Br J Clin Pharmacol. 1991 Feb;31(2):204-6. doi: 10.1111/j.1365-2125.1991.tb05517.x.
3
Microbial contamination of nebulization solution and its measures.
Biol Pharm Bull. 2006 Mar;29(3):503-7. doi: 10.1248/bpb.29.503.
4
Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution.
Br Med J (Clin Res Ed). 1987 May 9;294(6581):1197-8. doi: 10.1136/bmj.294.6581.1197-a.
5
Effect of preservative on the efficacy of terbutaline nebuliser solution in atopic asthma.
Thorax. 1993 May;48(5):566-8. doi: 10.1136/thx.48.5.566.
6
Intrathecal injections--a review of pharmaceutical factors.
Bull Parenter Drug Assoc. 1977 Sep-Oct;31(5):237-47.
7
[Preservatives in nebulizer solutions: risks without benefit].
J Pharm Belg. 1999 Mar-Apr;54(2):38-43.
8
Comparison of the efficacy of preservative free ipratropium bromide and Atrovent nebuliser solution.
Thorax. 1988 Jun;43(6):446-50. doi: 10.1136/thx.43.6.446.
9
"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs.
Pediatrics. 1997 Feb;99(2):268-78. doi: 10.1542/peds.99.2.268.
10
Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
Eur J Pharm Biopharm. 2008 Sep;70(1):260-9. doi: 10.1016/j.ejpb.2008.04.010. Epub 2008 Apr 24.
引用本文的文献
1
Nebulizers effectiveness on pulmonary delivery of alpha-1 antitrypsin.
Drug Deliv Transl Res. 2023 Oct;13(10):2653-2663. doi: 10.1007/s13346-023-01346-3. Epub 2023 Apr 25.
2
Nebulised Isotonic Hydroxychloroquine Aerosols for Potential Treatment of COVID-19.
Pharmaceutics. 2021 Aug 14;13(8):1260. doi: 10.3390/pharmaceutics13081260.
3
Inhaled antibodies: formulations require specific development to overcome instability due to nebulization.
Drug Deliv Transl Res. 2021 Aug;11(4):1625-1633. doi: 10.1007/s13346-021-00967-w. Epub 2021 Mar 25.
4
In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S11-20. doi: 10.1089/jamp.2009.0792.
5
Physicochemical compatibility of fluticasone-17- propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions.
Int J Chron Obstruct Pulmon Dis. 2007;2(4):599-607.
6
Assessment of different methods of inhalation from salbutamol metered dose inhalers by urinary drug excretion and methacholine challenge.
Br J Clin Pharmacol. 2005 Dec;60(6):605-10. doi: 10.1111/j.1365-2125.2005.02499.x.
7
In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system.
Thorax. 1996 Jan;51(1):75-7. doi: 10.1136/thx.51.1.75.
8
Effect of preservative on the efficacy of terbutaline nebuliser solution in atopic asthma.
Thorax. 1993 May;48(5):566-8. doi: 10.1136/thx.48.5.566.
9
Survey of colourings and preservatives in drugs.
BMJ. 1989 Sep 9;299(6700):649-51. doi: 10.1136/bmj.299.6700.649.
10
A non-bronchoconstrictor, bacteriostatic preservative for nebuliser solutions.
Br J Clin Pharmacol. 1991 Feb;31(2):204-6. doi: 10.1111/j.1365-2125.1991.tb05517.x.
本文引用的文献
1
THE POTENTIAL ROLE OF INHALATION THERAPY EQUIPMENT IN NOSOCOMIAL PULMONARY INFECTION.
J Clin Invest. 1965 May;44(5):831-9. doi: 10.1172/JCI105195.
2
Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide.
Am Rev Respir Dis. 1980 Dec;122(6):873-8. doi: 10.1164/arrd.1980.122.6.873.
3
Exercise increases sulfur dioxide-induced bronchoconstriction in asthmatic subjects.
Am Rev Respir Dis. 1981 May;123(5):486-91. doi: 10.1164/arrd.1981.123.5.486.
4
Anaphylaxis to a component of isoetharine (sodium bisulfite).
JAMA. 1982 Oct 22;248(16):2030-1.
5
Effect of pH on bronchial response to inhaled histamine.
Thorax. 1982 Feb;37(2):133-6. doi: 10.1136/thx.37.2.133.
6
Bacterial contamination of aerosol solutions used to treat cystic fibrosis.
Am J Hosp Pharm. 1982 Feb;39(2):308-9.
7
Airway response to water inhalation: a new test for "bronchial reactivity".
N Engl J Med. 1981 Sep 17;305(12):702. doi: 10.1056/NEJM198109173051221.
8
The effects of inhaled sulfuric acid on pulmonary function in adolescent asthmatics.
Am Rev Respir Dis. 1983 Aug;128(2):221-5. doi: 10.1164/arrd.1983.128.2.221.
9
Evaluation of ultrasonically nebulised solutions for provocation testing in patients with asthma.
Thorax. 1983 Apr;38(4):284-91. doi: 10.1136/thx.38.4.284.
10
Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone.
Am Rev Respir Dis. 1984 Feb;129(2):211-5.
Zotero 插件